Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observer-blinded randomized Phase III trial of IC51 (JE-PIV) versus JE-VAX for Japanese encephalitis prevention
2004-002474-36Phase 3Completed
- Sponsor
- Intercell AG
- Start
- Mar 2005
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Intercell AG. Primary endpoints: Seroconversion rate at day 56 and Geometric mean titer at day 56. Started Mar 2005; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on 2004-002474-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002474-36.